

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

### **巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **VOLUNTARY ANNOUNCEMENT**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with an update on the latest business development of the Group.

#### **POTENTIAL FORMATION OF A JOINT VENTURE & BUSINESS PLAN**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to provide an update that the Company is considering to form a joint venture in Singapore (the “**Proposed Joint Venture**”) with New Genetron Holding Limited (“**Genetron Health**”) and, potentially develop business in Indonesia, Malaysia and Singapore.

The Proposed Joint Venture is planned to incorporate a new entity in Indonesia and will be dedicated to designing, building and operating clinical molecular diagnostics laboratories with a focus on precision oncology, and, where appropriate, establishing local production facilities for IVD reagents and kits. In other words, the Proposed Joint Venture will set up advanced medical labs in Indonesia to provide advanced genetic testing including cancer screening, with an aim to help doctors catch diseases early and tailor treatments for patients.

The Proposed Joint Venture will focus on delivering advanced molecular diagnostics services (i.e. using cutting-edge lab tests to detect and understand diseases at a molecular level), particularly in the field of precision oncology (i.e. providing cancer care that is tailored to each patient’s unique gene mutations and cancer type).

Major offerings are notably early cancer screening (such as Genetron Health’s innovative HCCscreen and HCCscan products developed for hepatocellular carcinoma and based on NGS or qPCR technologies, with global recognition including FDA Breakthrough Device Designation granted to HCCscreen) (i.e. special blood tests to find liver cancer early, using advanced genetic technology), comprehensive genomic profiling (i.e. encompassing the simultaneous analysis of multiple cancer-associated genes to inform the selection of optimal therapeutic choices), minimal residual disease (MRD) monitoring (i.e. checking if tiny amounts of cancer remain after surgery using sensitive lab techniques), and non-invasive prenatal testing (“NIPT”) (i.e. a safe blood test for pregnant women to check the health of their baby without risk). Initial operations will prioritise laboratory-developed tests (LDT), with phased expansion to local manufacturing and broader insurance inclusion, leveraging Genetron Health’s technology and regulatory portfolio.

It is anticipated that the Proposed Joint Venture will engage in clinical and business partnerships with prominent Indonesian hospitals and healthcare institutions for sample collection, product validation and early-stage clinical adoption. A joint board and management team will be established for shared strategic oversight. The Proposed Joint Venture will also be responsible for all necessary regulatory filings with Indonesian authorities and strict compliance with local health and content requirements. There are plans to extend operations to Indonesia and into adjacent Southeast Asian markets as opportunities arise.

## **INFORMATION ABOUT THE GROUP**

The Group principally engages in the distribution of IVD products in the cities of PRC. The Group also manufactures medical films (used in X-Ray, Magnetic Resonance Imaging (MRI) and Computer Tomography (CT-scan) etc.) for Fujifilm in the PRC, and manufactures, markets and sells dental film and medical dry film products under the house brand “Yes!Star”.

## **INFORMATION ABOUT GENETRON HEALTH**

Genetron Health is a leading precision oncology platform company that specialises in multi-omics and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. As advised by Genetron Health, its product portfolio includes technologies such as HCCscreen and HCCscan for liver cancer early detection, which have received clinical recognition and regulatory milestones including the FDA Breakthrough Device Designation granted to HCCscreen. The company operates accredited laboratories and manufacturing facilities in China, and has established partnerships with hospitals and pharmaceutical companies for the advancement of cancer diagnostics and research.

## **REASONS FOR THE FORMATION OF THE JOINT VENTURE**

The Board believes that the Proposed Joint Venture with Genetron Health will enable the Group to leverage Genetron Health's front-running expertise in precision oncology, proprietary NGS technologies, patented sample preparation (including One-Step Seq library construction technology, Mutation Capsule technology), liquid biopsy, as well as its globally accredited clinical laboratory and regulatory infrastructure. By combining Genetron Health's innovative product portfolio and R&D with the Group's established distribution and manufacturing experience, the Proposed Joint Venture aims to accelerate the introduction and localisation of high-impact cancer screening, diagnosis and monitoring solutions throughout Indonesia and, in due course, Southeast Asia.

The formation of the Potential Joint Venture will accelerate the Group's growth in the fast-evolving diagnostics market, diversify revenue streams and enhance its competitive edge in delivering medical services. By entering a high-potential market through collaboration rather than starting independently, the Group may mitigate regulatory and operational risk, benefit from local and international networks and pursue opportunities arising from increasing healthcare spending and demand for advanced diagnostic solutions. The Board observes that Indonesia's healthcare sector presents strong growth prospects, driven by rising demand for quality diagnostics, improving insurance coverage and favourable population demographics. There remains significant opportunity for solutions such as NIPT, cancer screening and precision medicine. This synergistic partnership is expected to strengthen the Group's position in the medical technology industry and create sustainable long-term value for shareholders.

## **GENERAL**

The Board wishes to emphasise that the Potential Joint Venture contemplated may or may not proceed and that the parties have not entered into any memorandum of understanding or legally binding agreement as at the date of this announcement. The Company will make further announcements in relation to the Potential Joint Venture as and when appropriate in accordance with the Listing Rules. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Wang Chunlai**  
*CEO and executive Director*

Hong Kong, 20 October 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Chunlai, Mr. Qiao Jinrong and Ms. Liao Changxiang; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.*